Home › Trials › NCT06777485

Registry of liver cancer patients in China

China Liver Cancer Clinical Registry Cohort Database (HEAL)

Observational Anhui Provincial Hospital · NCT06777485

This study is creating a detailed database of liver cancer patients in China to help improve treatment and research for different types of liver cancer.

Quick facts

Study typeObservational
Enrollment10000 (estimated)
Ages18 Years and up
SexAll
SponsorAnhui Provincial Hospital Government
Locations38 sites (Anqing, Anhui and 37 other locations)
Trial IDNCT06777485 on ClinicalTrials.gov

What this trial studies

This observational study aims to create a standardized clinical information database for patients diagnosed with various forms of liver cancer, including hepatocellular carcinoma and its variants. Led by the Department of Hepatobiliary Surgery at the First Affiliated Hospital of the University of Science and Technology of China, the study involves collaboration with multiple hospitals across the country. The database will facilitate high-quality real-world clinical studies and enhance clinical research in liver cancer management.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older diagnosed with liver cancer, either through imaging or pathology tests.

Not a fit: Patients with severe concurrent diseases or those on long-term immunosuppressive therapy may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could improve the understanding and treatment of liver cancer through enhanced data collection and analysis.

How similar studies have performed: While similar observational studies have been conducted, this specific registry approach is relatively novel in the context of liver cancer in China.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Age ≥ 18 years, no gender limit
* Patients without surgery are initially diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of imaging and laboratory tests, or patients with surgery are diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of pathologic tests
* Signed informed consent, good compliance, willingness to accept follow-up and provide blood and postoperative pathology residual samples

Exclusion Criteria:

* Combination of severe central nervous system disease, respiratory disease, autoimmune disease, chronic renal insufficiency, long-term use of immunosuppressive drugs, combination of severe uncontrolled infections
* Concurrent active cardiovascular disease, cerebrovascular accident within 6 months, myocardial infarction, unstable angina pectoris, or congestive heart failure of class II or greater according to the New York Heart Association criteria, severe arrhythmia requiring medication
* Pregnant or breastfeeding women
* Participation in other therapeutic clinical trials during the course of the patient's illness in which the treatment cannot be specified or information about the treatment cannot be collected

Where this trial is running

Anqing, Anhui and 37 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Liver Cancer
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.